Maison Surgiris has designed the DERMARIS an innovative and intelligent dermatological lighting system featuring exclusive patented MOTIONMATICtechnology to treat actinic keratosis (AK) using photodynamic therapy(PDT). Our DERMARIS lighting ensures effectiveeffective and painless treatment of Actinic Keratosis while achieving positive results.
In addition, the DERMARIS is the essential lighting solution for dermatologists worldwide in the treatment of their patients.
Ergonomic & easy to handle, our DERMARIS dermatological lighting offers numerous advantages:
- Ease of use : The light is compact and space-saving, making it easy to set up for the patient (in less than 2 minutes).
- Unparalleled patient comfort : treatment is silent
- Long-term use: more than 30,000 treatments possible with a treatment time of 2 hours
- Sustainable lighting: DERMARIS offers a service life of 60,000 hours and can also be used as examination lighting.
What is Actinic Keratosis?
Actinic keratosis is one of the main reasons for consulting a dermatologist. This skin lesion appears as a red, crusty lesion that is rough to the touch. It is caused by chronic and intense exposure to the sun and can develop into skin cancer.
How to treat Actinic Keratosis?
Photodynamic therapy can be used to treat actinic keratosis. The treatment involves applying a cream to the area to be treated, which creates the photosensitizer: protoporphyrin IX (PpIX). Exposure to white light begins between 5 and 10 minutes after the cream is applied. White light is more effective than red or blue light because it excites all of the PpIX absorption peaks.
What is photodynamic therapy?
Photodynamic therapy (PDT) is a medical technique that aims to destroy precancerous tissue through the use of photosensitizing substances combined with a light source.
DERMARIS has been used in numerous clinical studies involving 38 patients, with results demonstrating its effectiveness in the treatment of Actinic Keratosis:
- 58% of patients had no more KA lesions 3 months after treatment
- 32% of patients required a second AWL-PDT treatment
- 10% of patients had one to four KA lesions after 2 treatments.
- 33 of the 38 patients ( 87%) experienced no pain during treatment.
- Five patients (13%) rated their pain level as 1 on a scale of 10.
- 34% ofpatients report no discomfort
- 63% of patients report mild discomfort
If you are interested in our dermatological lighting, please visit the product page dedicated to DERMARIS, or contact us directly via our contact form.